Adial Pharmaceuticals (ADIL) Operating Expenses (2017 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Adial Pharmaceuticals was $57.68 million, up 594.8% year-over-year; for FY2025, it came in at $7.8 million, down 5.9% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of -6.5% (FY2020 to FY2025).
• In prior years, Adial Pharmaceuticals' Operating Expenses was $8.28 million in FY2024 (+20.3%), $6.89 million in FY2023 (-36.6%), $10.86 million in FY2022 (-43.7%) and $19.29 million in FY2021 (+76.5%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses in data going back to Q2 2017.
• On a year-over-year basis, Operating Expenses increased in three of the last seven quarters, with growth averaging 6.0%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2021, with growth of 72.3%; the weakest was Q4 2022, with a decline of 56.6%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $2 million (Q1 2026), $1.89 million (Q4 2025) and $1.76 million (Q3 2025).